[{"id":"95beae3b-8f0c-4d74-87ac-938908f3ca15","acronym":"","url":"https://clinicaltrials.gov/study/NCT04792593","created_at":"2021-03-11T12:53:43.576Z","updated_at":"2024-07-02T16:36:33.425Z","phase":"","brief_title":"Senl-h19 CAR-T Cell Injection in the Treatment of Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia","source_id_and_acronym":"NCT04792593","lead_sponsor":"Hebei Senlang Biotechnology Inc., Ltd.","biomarkers":" IFNG • IL6 • TNFA • IL10 • CD7","pipe":" | ","alterations":" CD19 positive","tags":["IFNG • IL6 • TNFA • IL10 • CD7"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • S1904 • Senl-h19"],"overall_status":"Recruiting","enrollment":" Enrollment 15","initiation":"Initiation: 12/03/2020","start_date":" 12/03/2020","primary_txt":" Primary completion: 12/10/2021","primary_completion_date":" 12/10/2021","study_txt":" Completion: 02/10/2022","study_completion_date":" 02/10/2022","last_update_posted":"2021-03-11"}]